New ADHD Stimulant OK’d; Anticonvulsant for Depression?

The FDA approved Azstarys, a new once-daily combination serdexmethylphenidate and immediate-release d-methylphenidate stimulant medication, for ADHD in patients ages 6 and older, KemPharm announced.

Should ADHD get a moniker overhaul? (Scientific American)

Monitoring dynamic changes in suicidal thoughts during a hospitalization was better at predicting post-discharge suicide attempts than only using baseline admission data. (JAMA Network Open)

Could the anticonvulsant ezogabine also relieve depression and anhedonia? (American Journal of Psychiatry)

Sustaining just one head injury can increase one’s risk of dementia decades later. (Alzheimer’s & Dementia)

A new study pinpointed a link between neuroinflammation and bipolar disorder. (Gizmodo)

Meghan Markle, in an interview with Oprah Winfrey, opened up about her struggle with suicidal thoughts. (MedPage Today)

Bad news for Acadia Pharmaceuticals in its quest to have pimavanserin (Nuplazid) approved for dementia-related psychosis hallucinations and delusions — the FDA faulted the firm’s application for “deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time.”